AstraZeneca are taking a keen interest in cell therapy for cardiovascular disease. Here the Global Head of Research and Early Clinical Development at AstraZeneca is talking about MESO’s dream trial:
“There are also mesenchymal stem cells-based approaches in the clinic today and some rather large Phase 3 trials are being finalized this year. It will be interesting to see the outcome of these!”
Phase 3 DREAM HF-1 read-out, page-272
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
94.0¢ |
Change
-0.020(2.08%) |
Mkt cap ! $1.090B | |||
| Open | High | Low | Value | Volume |
| 95.5¢ | 97.0¢ | 94.0¢ | $552.4K | 580.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 71618 | 94.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.5¢ | 55899 | 52 |
View Market Depth
| Last trade - 12.05pm 13/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |